NCT02709889 2020-10-19Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid TumorsAbbViePhase 1/2 Terminated200 enrolled 21 charts
NCT04001725 2019-11-13OPTIMALFondazione IRCCS Istituto Nazionale dei Tumori, MilanoPhase 2 Unknown110 enrolled